KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) EBT (2016 - 2025)

Supernus Pharmaceuticals has reported EBT over the past 15 years, most recently at -$1.9 million for Q4 2025.

  • Quarterly EBT fell 107.25% to -$1.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$49.0 million through Dec 2025, down 150.1% year-over-year, with the annual reading at -$49.0 million for FY2025, 150.1% down from the prior year.
  • EBT was -$1.9 million for Q4 2025 at Supernus Pharmaceuticals, up from -$58.0 million in the prior quarter.
  • Over five years, EBT peaked at $44.9 million in Q3 2024 and troughed at -$58.0 million in Q3 2025.
  • The 5-year median for EBT is $10.4 million (2021), against an average of $9.3 million.
  • Year-over-year, EBT surged 2564.85% in 2024 and then tumbled 2499.59% in 2025.
  • A 5-year view of EBT shows it stood at $2.1 million in 2021, then skyrocketed by 1613.31% to $35.1 million in 2022, then plummeted by 97.18% to $990000.0 in 2023, then surged by 2564.85% to $26.4 million in 2024, then plummeted by 107.25% to -$1.9 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's EBT are -$1.9 million (Q4 2025), -$58.0 million (Q3 2025), and $16.7 million (Q2 2025).